biostudies-literatureShuster HPrisma Health Cancer Institute Philanthropy GrantDepartment of Biomedical Sciences at the University of South Carolina School of Medicine GreenvilleTransformative Seed Grant Program of the Health Sciences Center at Prisma HealthSargent FoundationPrisma Health Cancer Institute1165https://www.ebi.ac.uk/biostudies/studies/S-EPMC10969284biostudies-literatureUnknown16(6)Galectins play a pivotal role in lung cancer oncogenic pathways, influencing apoptosis, angiogenesis, and tumor metastasis. Biomarkers that diagnose, prognose, and guide cancer treatment are crucial, with galectins having the biomarker potential for non-small cell lung cancer (NSCLC). Using enzyme-linked immunosorbent assay (ELISA), we assessed serum galectin-1, -3, and -9 levels in NSCLC patients. A retrospective chart review was performed to examine patient demographics, cancer stage, tumor biology, cancer treatment, and patient outcomes. Galectin levels were then compared across these factors. In this exploratory analysis, galectin-3 levels were significantly lower in patients with squamous cell lung cancer (<i>p</i> = 0.0019) and in patients exposed to chemotherapy (<i>p</i> = 0.0375).CancersExploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer.PMC10969284NAShuster HMartin JCFunkhouser AAllen LHeo MEdenfield WJBlenda AVfalseExploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer.Galectins play a pivotal role in lung cancer oncogenic pathways, influencing apoptosis, angiogenesis, and tumor metastasis. Biomarkers that diagnose, prognose, and guide cancer treatment are crucial, with galectins having the biomarker potential for non-small cell lung cancer (NSCLC). Using enzyme-linked immunosorbent assay (ELISA), we assessed serum galectin-1, -3, and -9 levels in NSCLC patients. A retrospective chart review was performed to examine patient demographics, cancer stage, tumor biology, cancer treatment, and patient outcomes. Galectin levels were then compared across these factors. In this exploratory analysis, galectin-3 levels were significantly lower in patients with squamous cell lung cancer (<i>p</i> = 0.0019) and in patients exposed to chemotherapy (<i>p</i> = 0.0375).2024-01-01T00:00:00Z2024 Mar2026-07-08T03:10:12.245Z2026-07-08T03:07:39.416ZS-EPMC109692843853950010.3390/cancers16061165